-transparent.png){kind=logo}
We report the case of a 27-year-old woman with a prolactin-secreting macroadenoma of the pituitary gland who was under treatment with a new dopamine agonist, Sandoz CV 205-502. Immediately after diagnosis of a 12 x 10 mm intrasellar prolactinoma, treatment with CV 205-502 was begun at a daily dose of 0.075 mg. Under this low dose, prolactin in the serum normalized after 4 weeks, the initial hormone value being 189.9 ng/ml. After 6 months of therapy there was still a 6 x 6 mm tumor, and after 15 months of treatment the pathological process could no longer be observed with magnetic resonance imaging. In the 20th month of therapy the patient became pregnant. An ovulatory menstrual cycle had been present for a few months.
W J Fassbender, and
H Stracke, and
G Bachmann, and
W Rau, and
K Federlin
April 1994,
Clinical endocrinology,
W J Fassbender, and
H Stracke, and
G Bachmann, and
W Rau, and
K Federlin
July 1991,
European journal of obstetrics, gynecology, and reproductive biology,
W J Fassbender, and
H Stracke, and
G Bachmann, and
W Rau, and
K Federlin
March 1991,
British journal of obstetrics and gynaecology,
W J Fassbender, and
H Stracke, and
G Bachmann, and
W Rau, and
K Federlin
May 1990,
Annals of internal medicine,
W J Fassbender, and
H Stracke, and
G Bachmann, and
W Rau, and
K Federlin
September 1988,
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology,
W J Fassbender, and
H Stracke, and
G Bachmann, and
W Rau, and
K Federlin
May 1995,
European journal of endocrinology,
W J Fassbender, and
H Stracke, and
G Bachmann, and
W Rau, and
K Federlin
August 1991,
Acta endocrinologica,
W J Fassbender, and
H Stracke, and
G Bachmann, and
W Rau, and
K Federlin
December 1989,
Neurosurgery,
W J Fassbender, and
H Stracke, and
G Bachmann, and
W Rau, and
K Federlin
September 1988,
Clinical endocrinology,
W J Fassbender, and
H Stracke, and
G Bachmann, and
W Rau, and
K Federlin
February 1989,
The Journal of clinical endocrinology and metabolism,
